CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 78 enrolled
Drug / intervention
Topical Testosterone Solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01893281
NCT01893281Phase 4Completed
CompareCT.gov

The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel

Eli Lilly and Company·interventional·Posted Jul 9, 2013·Updated Oct 27, 2014

In Brief

A Phase 4 clinical trial evaluating Topical Testosterone Solution for Hypogonadism. Completed, enrolled 78 participants across 21 sites.

Detailed Summary

This study will evaluate if testosterone solution can raise testosterone hormone levels into the normal range after treatment for up to 9 Weeks, in those participants with a documented history of subtherapeutic levels \[total testosterone \<300 nanograms per deciliter (ng/dL)\] when previously treated with a topical testosterone gel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 9, 2013
Enrollment StartJul 1, 2013
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.0 years ago

Interventions

Topical Testosterone Solutiondrug

Administered topically to axillae.